Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Donatella Romaniello(Weizmann Institute of Science), Yosef Yarden(Weizmann Institute of Science)
Cancers
August 24, 2020
Cited by 60


Related Papers